Resurgex Select Focus of Childrens Study

PARAMUS, N.JColumbia University has chosen Resurgex Select® (from Millennium Biotechnologies Group Inc.) to be the focus of a multicenter, clinical trial to test its effectiveness in treating pediatric oncology patients.

The clinical study is the first to test the effectiveness of the proprietary nutritional blend contained in Resurgex's nutritional supplement in preserving lean muscle mass and quality of life in pediatric cancer patients. The clinical study protocol titled "Promass Nutrition Intervention Using High Calorie Protein Supplement to Preserve Lean Body Mass," is scheduled to occur during the summer of 2010 and last for 12 weeks. The study will take place at four separate test sites: Columbia University Division of Pediatric Oncology, St. Jude Children's Research Hospital (SJCRH), Alberta Health Services and the Regional Cancer Center (RCC) at Capital Health.

Columbia University goal is to determine the supplement's ability to be an effective treatment in minimizing or eliminating the effects of cancer treatment on children's bodies. The specific objectives of the clinical trial are to validate that the company's Resurgex Select's® acceptance in pediatric patients based on its taste, color and texture as well as its effectiveness in preventing the loss of lean body mass and impact on quality of life, as measured by the Peds QL standard, in children with brain tumors that are undergoing therapy.  

"The company is optimistic its Resurgex supplement will provide a greater improvement in the nutrition of pediatric oncology patients than any competing products, and both parties are anxious to launch this trial immediately following I.R.B. approval next month, stated Mark Mirken, Chairman and CEO of Millennium Biotechnologies Group. Additionally, we believe Resurgex's superior taste and texture will give it a higher level of acceptability by children than all other nutritional products, which is a key component of this trial's success.

Millennium Biotechnologies Group will provide the clinical study with its Resurgex product and four "Multi-Frequency, Segmented Bioelectric Impedance" machines needed to measure lean body mass.